The FDA-Approved Antiviral Raltegravir Inhibits Fascin1-Dependent Invasion of Colorectal Tumor Cells In Vitro and In Vivo.
Begoña Alburquerque-GonzálezÁngel Bernabé-GarcíaManuel BernabéJavier Ruiz-SanzFernando Feliciano López-CalderónLeonardo GonnelliLucia BanciJorge Peña-GarcíaIrene LuqueFrancisco José NicolásMaría Luisa Cayuela-FuentesEnrico LuchinatHoracio Pérez SánchezSilvia Montoro-GarcíaPablo Conesa-ZamoraPublished in: Cancers (2021)
The current data show the in vitro and in vivo efficacy of the antiretroviral drug RAL in inhibiting human colorectal cancer cells invasion and metastasis in a Fascin1-dependent manner.
Keyphrases
- cell migration
- hiv infected patients
- endothelial cells
- hiv infected
- human immunodeficiency virus
- signaling pathway
- electronic health record
- hiv aids
- hiv positive
- induced pluripotent stem cells
- pluripotent stem cells
- emergency department
- drug administration
- data analysis
- adverse drug
- men who have sex with men
- artificial intelligence